| Cat.No. | Name | Information |
|---|---|---|
| M2050 | GSK2636771 | GSK2636771 is a potent, orally available and specific PI3K p110β (PI3K beta, PI3Kβ) inhibitor. |
| M1925 | LY294002 | LY294002 is a highly selective PI3K inhibitor with IC50 values of 0.31, 0.73, 1.06 and 6.60 μM for PI3Kβ, PI3Kα, PI3Kδ and PI3Kγ respectively. LY294002 also inhibits CK2 with an IC50 of 98 nM. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4 μM. |
| M2296 | 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM, respectively. |
| M1715 | GDC-0941 (Pictilisib) | GDC-0941 is a selective and potent inhibitor of Class I PI3K, p110a IC50=0.003uM, U87MG IC50=0.95μM. |
| M1984 | PF-04691502 | PF-04691502 is a potent and selective, ATP-competitive PI3K/mTOR inhibitor with IC50 of 7.5 nM and 3.8 nM of AKT T308 and AKT S473, respectively. |
| M2053 | Wortmannin (KY 12420) | Wortmannin (KY 12420) is a specific, covalent inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase) with IC50 of 3 nM. |
| M1680 | BKM120 (Buparlisib) | BKM120 (NVP-BKM120) is a potent and highly specific oral pan-class I PI3K inhibitor. |
| M1819 | A66 | A66 is a potent and specific inhibitor of PI3K p110α with IC50 values of 32, 30 and 43 nM for p110α, p110α/E545K and p110α/H1047R. |
| M1671 | BEZ235 | BEZ235 (NVP-BEZ235) is a potent dual PI3K and mTOR inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively. |
| M1773 | PI-103 | PI-103 is a potent, ATP-competitive PI3K,cell-permeable,inhibitor.The IC50 values are 2, 8, 20, 26, 48, 83, 88, 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γrespectively. |
| M28374 | GSK-A1 | GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα) inhibitor with a pIC50 of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC50 of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research. |
| M28347 | LAS191954 | LAS191954 is a potent, selective and orally active PI3Kδ inhibitor for inflammatory diseases treatment, with an IC50 of 2.6 nM. |
| M28143 | Roginolisib | Roginolisib (MSC2360844; IOA-244) is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib shows highly selective against a panel of 278 additional kinases. |
| M28086 | Dezapelisib | Dezapelisib (NCB040093) is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ). Dezapelisib is a promising research strategy for select R/R B-cell lymphomas. |
| M28083 | SAR-260301 | SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC50 of 23 nM. |
| M28008 | BEBT-908 | BEBT-908 (PI3Kα inhibitor 1) is a selective PI3Kα inhibitor with an IC50<0.1 μM, it also inhibits HDAC (0.1 μM≤IC50≤1 μM) . |
| M27971 | DS-7423 | DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity. |
| M27677 | GNE-490 | GNE-490, a (thienopyrimidin-2-yl)aminopyrimidine, is a potent pan-PI3K inhibitor with IC50s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. GNE-490 has >200 fold selectivity for mTOR (IC50=750 nM). GNE-490 shows potent suppression efficacy profile against MCF7.1 breast cancer xenograft model. |
| M21296 | PF-06843195 | PF-06843195 is a highly selective PI3Kα inhibitor with an IC50 of 18 nM in Rat1 fibroblasts.The Ki of PF-06843195 acting on PI3Kα and PI3Kδ is less than 0.018 nM and 0.28 nM, respectively.PF-06843195 has a significant inhibitory effect on PI3K/mTOR signaling pathway and had a long-lasting anti-tumor effect. |
| M21171 | AZD8154 | AZD8154 is a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory diseases. |
| M21093 | NVP-CLR457 | NVP-CLR457 is an orally administered, non-CNS-penetrating, pan-IA-like phosphoinositide 3-kinase (PI3K) inhibitor.NVP-CLR457 shows a significant dose-dependent PK / PD / efficacy relationship.NVP-CLR457 has antitumor activity. |
| M20796 | ME-401 | ME-401 (PWT-143, P110δ-IN-1) is an oral, potent and selective inhibitor of Phosphatidylinositol 3-Kinase (PI3K) P110δ with IC50 of 0.6 nM in cellular assay. |
| M20632 | Selective PI3Kδ Inhibitor 1 (compound 7n) | Selective PI3Kδ Inhibitor 1 (compound 7n) is an inhibitor of PI3Kδ with an IC50 of 0.9 nM and >1000-fold selectivity against other class I PI3K isoforms [PI3K α/γ/β=3670/1460/21300 nM]. |
| M20610 | AMG319 | AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2. |
| M20589 | KDU691 | KDU691 is a Plasmodium PI4K -specific inhibitor with IC50 values of 0.18 μM and 0.061 μM against hypnozoite forms and liver schizontsm, respectively. |
| M20587 | BQR695 | BQR695 is a quinoxaline that displays sub-micromolar potency against human PI4KIIIβ (IC50~90 nM). |
| M20353 | WAY-278705 | WAY-278705 is a phosphoinositide 3-kinase (PI3 kinase) modulator. |
| M20344 | WAY-299017 | WAY-299017 is a selective inhibitor of mutant H1047R phosphoinositide- 3-kinase (PI3Ka). |
| M20331 | WAY-232261 | WAY-232261 is a PI3 kinase inhibitor. |
| M20260 | WAY-647361 | WAY-647361 is a PI3 kinase inhibitor |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
